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LETTER TO THE EDITOR
Conceptions of the pathophysiology 
of happy hypoxemia in COVID-19
Sebastiaan Dhont1* , Eric Derom1,2, Eva Van Braeckel1,2, Pieter Depuydt1,3 and Bart N. Lambrecht1,2,4
Abstract 
In their letter-to-the-editor entitled “Misconceptions of pathophysiology of happy hypoxemia and implications for 
management of COVID-19”, Tobin et al. (Respir Res 21:249, 2020) debated our views on happy hypoxemia in COVID-
19 (Respir Res 21:198, 2020). We thank the authors for their interesting comments and alternative viewpoints, and we 
would like to clarify several important aspects raised.
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Letter
We read with interest the letter-to-the-editor by Tobin, 
Jubran and Laghi concerning our article on happy hypox-
emia in COVID-19 [1, 2]. The authors challenged our 
narrative review with some interesting thoughts.
We agree with Tobin et  al. [1] that “the essential 
point about happy hypoxemia is that patients can be 
profoundly hypoxic and yet exhibit no abnormality in 
breathing pattern”. This is worrying indeed, as the sever-
ity of hypoxemia is independently associated with in-
hospital mortality and in particular of concern among 
patients with chronic compromised organ perfusion such 
as ischemic heart disease [3–5]. However, in our experi-
ence, subtle changes in breathing pattern may serve as 
early warning signs of impending hypoxemic respira-
tory failure in COVID-19. The respiratory drive shifts 
minimally in mild hypoxemia, but when arterial oxygen 
tension drops below a critical threshold, a rise in minute 
volume does occur [6–9]. That is why we stressed the 
importance of interpreting pulse oximetry results in the 
light of the respiratory rate. The oxyhemoglobin-dissoci-
ation curve may indeed shift to the right when COVID-
19 disease progresses [1]. Although mainly a theoretical 
concept—some authors claim a leftward shift [10]—the 
mechanisms and importance of this phenomenon require 
further investigation.
Tobin and colleagues [1] state that there is no evidence 
for patient self-inflicted lung injury (P-SILI), neither in 
COVID-19 nor in other conditions leading to acute res-
piratory failure. In 2010, Papazian et  al. revealed that 
early administration of neuromuscular blocking agents 
improved 90-day survival in ARDS [11]. The mechanisms 
underlying this beneficial effect remain controversial, but 
the potential risk of spontaneous breathing efforts (also 
investigated in non-intubated patients [12, 13]) and the 
subsequent need for prevention of these efforts dur-
ing mechanical ventilation have been highlighted and 
extensively discussed. Experimental observations have 
pointed out that P-SILI in humans can lead to pulmonary 
edema following airway obstruction, due to large varia-
tions in pleural pressure [14, 15]. This mechanism may 
also be responsible for pulmonary edema resulting from 
re-expansion of a pneumothorax and edema formation 
in a minority of patients experiencing a severe asthma 
attack [16, 17]. Additionally, the spontaneous occurrence 
of pneumomediastinum in non-intubated patients with 
COVID-19 may be an example of a so-called self-inflicted 
lung injury [18, 19]. In closing, we believe that P-SILI 
remains an interesting hypothesis in the disease progres-
sion of COVID-19 [20]. Otherwise, we agree with Tobin 
and colleagues [1, 21] that there is insufficient evidence to 
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warrant premature intubation in order to prevent P-SILI 
in COVID-19, and that there are much simpler measures 
to tackle (happy) hypoxemia, such as providing supple-
mental oxygen.
Tobin et  al. [1] ask if there is evidence indicating that 
specific measures will ameliorate cytokine storm and if 
tackling these targets will benefit COVID-19 patients. 
Although thoughts on immunomodulatory therapeutic 
targets in COVID-19 were only mentioned in the margin 
of our review on happy hypoxemia, data on the role of 
cytokine release syndrome (CRS) have been increasingly 
reported since. Increased levels of pro-inflammatory 
cytokines (e.g., IFNα, IFNγ, IL-1β, IL-6, IL-12, IL-18, 
IL-33, TNFα, TGFβ) and chemokines (e.g., CXCL10, 
CXCL8, CXCL9, CCL2, CCL3, CCL5) are associated 
with pulmonary inflammation and ARDS in patients 
infected by SARS and MERS-CoV infections [22, 23]. 
Huang et al. reported that COVID-19 patients also show 
high titers of these cyto- and chemokines and, more 
importantly, the cytokine release syndrome (CRS) seem 
to emerge as a main factor driving a more severe clini-
cal course [24]. A multicenter study in China revealed 
that higher levels of serum IL-6 were correlated with 
fatal outcome in COVID-19 [25]. Similar studies by Gao 
et  al. and Chen et  al. reported that levels of IL-10, IL-6 
and TNF-α were higher in severe COVID-19 [25, 26]. 
The main contributors to the interplay of the CRS seem 
to be IL-1, IL-6 and TNF-α and several biological agents 
targeting these cytokines are being extensively studied in 
COVID-19 [27]. Tocilizumab, for example, is a human-
ized monoclonal antibody that binds IL-6 receptors and 
has proven to be valuable in treatment of cytokine storm 
triggered by chimeric antigen receptor T-cell therapy 
[27]. Encouraging results have been reported on its use 
in severe COVID-19 on length of ICU stay, ventilation-
free survival, and also on oxygenation parameters [27, 
28]. These findings explain why we eagerly await the final 
results of ongoing international randomized trials, that 
not only look at blockade of individual cytokines, but also 
at combined IL-1 and IL-6 blockade (e.g. NCT04320615, 
NCT04372186, NCT04331808 and NCT04330638) [28].
In conclusion, we thank the authors for their critical 
comments. Our main intention was to provide a thought-
provoking review on the potential mechanisms leading 
to the phenomenon of happy hypoxemia in COVID-
19, more than providing therapeutic guidelines, which 
should always be based on scientific evidence.
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